Kidney transplant patients' immune response to common virus tracked after drug switch
NCT ID NCT05708534
First seen Jun 05, 2026 · Last updated Jun 19, 2026 · Updated 2 times
Summary
This study follows 28 kidney transplant recipients who are switching from one anti-rejection drug (anticalcineurin) to another (belatacept). Researchers want to see how this change affects the immune system's ability to fight the common CMV virus. Participants will have blood tests at the start, 3 months, and 6 months to measure CMV-fighting T-cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Rouen Hospital
Rouen, 76031, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.